drugset / Trial / NCT01045369
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects
Phase 4
Completed
30 enrolled
Therapeutic Concepts
Abbott · collabBluKyne · collabTibotec, Inc · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if using a combination of other drug classes, like the ones that Kaletra® and Intelence™ belong to, can still help reduce the amount of HIV in your blood. Using Kaletra® and Intelence™ without other drugs is not approved by the FDA and so their use in this study is experimental.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-04
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etravirine | Small molecule | 200 mg | — |
| Subject | Ritonavir | Other / unclassified | 400 mg | — |